Early Clinical Outcomes of the Preserflo Microshunt Device
DOI:
https://doi.org/10.48560/rspo.25962Keywords:
Glaucoma/surgery, Glaucoma Drainage Implants, Filtering Surgery, Intraocular PressureAbstract
INTRODUCTION: The purpose of this study was to assess the efficacy and safety profile of the Preserflo® Microshunt device, which is an ab externo sub-Tenon’s aqueous shunt approved for the surgical treatment of glaucoma,
METHODS: Retrospective single-center observational study. Patients who underwent stan- dalone or combined phacoemulsification-Preserflo® Microshunt implantation with a minimum of 3 months of post-operative follow-up were included. Primary outcome measures included surgi- cal success defined as a ≥ 30% decrease in IOP from baseline and unmedicated IOP ≤18 mmHg. Secondary outcomes included number of hypotensive drops and adverse effects.
RESULTS: Ninety-two (92) eyes from 77 patients (mean±SD age 68±18 years) were included, most of which underwent standalone surgery (n=74 eyes; 80%). Average post-operative follow-up time was 9±6 months, with over three quarters of eyes (n=70; 76%) completing at least 6 months of follow-up and a third (n=30; 33%) with at least 12 months. Mean IOP was significantly reduced from a baseline measurement of 22±5.8 mmHg throughout follow-up, with a 12-month IOP of 13.9±4.8 mmHg (p<0.0001). Mean number of medications was reduced from 2.8±0.9 to 0.5±0.9 at last follow-up (p<0.0001), with 75% of eyes remaining drop-free throughout follow-up. Absolute success at 12 months was 46% and 64% if medication was allowed (qualified). Complications included self-limited intra-operative bleeding or post-operative hyphema (total n=9; 10%), and shallow anterior chamber (n=4; 4%). No major or sight-threatening complication was recorded.
CONCLUSION: Early audit of real-world data from Preserflo® use suggests this to be a safe and effective surgical option for the treatment of medically uncontrolled glaucoma.
Downloads
References
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-anal- ysis. Ophthalmology. 2014;121:2081-90. doi:10.1016/j.oph- tha.2014.05.013
Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Heal. 2021;9:e144-e160. doi:10.1016/S2214-109X(20)30489-7
Vinod K, Gedde SJ, Feuer WJ, Panarelli JF, Chang TC, Chen PP, et al. Practice Preferences for Glaucoma Surgery. J Glaucoma. 2017;26:687-693. doi:10.1097/IJG.0000000000000720
Rathi S, Andrews CA, Greenfield DS, Stein JD. Trends in Glaucoma Surgeries Performed by Glaucoma Subspecialists versus Nonsubspecialists on Medicare Beneficiaries from 2008 through 2016. Ophthalmology. 2021;128:30-8. doi:10.1016/j. ophtha.2020.06.051
Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study After Five Years of Follow-up. Am J Ophthalmol. 2012;153:789-803.e2. doi:10.1016/j.ajo.2011.10.026
Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed IK, et al. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up. Ophthalmology. 2020;127:333-45. doi: 10.1016/j.ophtha.2019.10.002.
Chu C, Liebmann JM, Ciof GA, Blumberg DM, Al-aswad LA. Reoperations for Complications Within 90 Days After Glaucoma Surgery. J Glaucoma. 2020;29:344-6. doi:10.1097/ IJG.0000000000001484
Conlon R, Saheb H, Ahmed IIK. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017;52:114-24. doi:10.1016/j. jcjo.2016.07.013
Coleman AL, Richter G. Minimally invasive glaucoma sur- gery: current status and future prospects. Clin Ophthalmol. 2016:189. doi:10.2147/OPTH.S80490
European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th ed. Amsterdam: Publicomm; 2020.
Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, et al. The use of poly(styrene-block-isobutyleneblock- styrene) as a microshunt to treat glaucoma. Regen Biomater. 2016;3:137-42. doi:10.1093/RB/RBW005
Batlle JF, Fantes F, Riss I, Pinchuk L, Alburquerque R, Kato YP, et al. Three-year follow-up of a novel aqueous humor microshunt. J Glaucoma. 2016;25:e58-e65. doi:10.1097/ IJG.0000000000000368
Shaarawy TM, Aptel F, Beckers HJ. 12-month interim results of a multicentre open-label study of the InnFocus MicroShunt® Glaucoma Drainage System in patients with primary open- angle glaucoma. Invest Ophthalmol Vis Sci. 2018;59:3457.
Fea AM, Laffi GL, Martini E, Economou MA, Caselgrandi P, Sacchi M, et al. Effectiveness of MicroShunt in Patients with Primary Open-Angle and Pseudoexfoliative Glaucoma: A Retrospective European Multicenter Study. Ophthalmol Glaucoma. 2022;5:210-8. doi: 10.1016/j.ogla.2021.08.005.
Schlenker MB, Durr GM, Michaelov E, Ahmed IK. Intermedi- ate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt With Mitomycin C. Am J Ophthalmol. 2020;215:141-53. doi:10.1016/j.ajo.2020.02.020
Beckers HJ, Aptel F, Webers CA, Bluwol E, Martínez-de-la- Casa JM, García-Feijoó J, et al. Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study. Ophthalmol Glaucoma. 2022;5:195-209. doi: 10.1016/j.ogla.2021.07.008.
Martínez-de-la-Casa JM, Saenz-Francés F, Morales-Fernandez L, et al. Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients. Sci Rep. 2021;11:1-8. doi:10.1038/s41598-021-95217-x
Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, et al. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study. Ophthalmol- ogy. 2021;128:1710-21. doi: 10.1016/j.ophtha.2021.05.023.
Shaarawy TM, Sherwood MB, Grehn F, editors. Guidelines on Design and Reporting of Surgical Trials - World Glaucoma Association. Philadelphia: Kugler Publications; 209.
Pillunat KR, Herber R, Haase MA, Jamke M, Jasper CS, Pil- lunat LE. PRESERFLOTM MicroShunt versus trabeculecomy: first results on efficacy and safety. Acta Ophthalmol. 2022;100:e779-e790. doi: 10.1111/aos.14968.
Gizzi C, Costa G, Servadei R, Abed E, Ning B, Sharma A, et al. A case of malignant glaucoma following insertion of PreserfloTM MicroShunt. Eur J Ophthalmol. 2022;32:NP115-9. doi: 10.1177/11206721211003492.
Micheletti E, Riva I, Bruttini C, Quaranta L. A Case of Delayed- onset Hemorrhagic Choroidal Detachment after PreserFlo Microshunt Implantation in a Glaucoma Patient under Anti- coagulant Therapy. J Glaucoma. 2020;29:E87-E90. doi:10.1097/ IJG.0000000000001584
Agrawal P, Bradshaw SE. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery ( MIGS ) in Primary Open-Angle Glaucoma. Ophthalmol Ther. 2018;7:49-73. doi:10.1007/s40123-018-0131-0 Derick RJ, Evans J, Baker ND. Combined phacoemulsification and trabeculectomy versus trabeculectomy alone: a com- parison study using mitomycin-C. Ophthalmic Surg Lasers. 1998;29:707-13.
Marcos Parra MT, Salinas López JA, López Grau NS, Ceaus- escu AM, Pérez Santonja JJ. XEN implant device versus trabeculectomy, either alone or in combination with phacoemulsi- fication, in open-angle glaucoma patients. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:1741-50. doi: 10.1007/s00417-019- 04341-y.
Siriwardena D, Kotecha A, Minassian D, Dart JK, Khaw PT. Anterior chamber flare after trabeculectomy and after phacoemulsification. Br J Ophthalmol. 2000;84:1056-7. doi:10.1136/ bjo.84.9.1056
Kerr NM, Ahmed IIK, Pinchuk L, Sadruddin O, Palmberg PF. PRESERFLO MicroShunt. In: Minimally Invasive Glaucoma Surgery. Berlin: Springer; 2021. p.91-103.
Kirwan JF, Lockwood AJ, Shah P, et al. Trabeculectomy in the 21st century: A multicenter analysis. Ophthalmology. 2013;120:2532-9. doi:10.1016/j.ophtha.2013.07.049
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Revista Sociedade Portuguesa de Oftalmologia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Do not forget to download the Authorship responsibility statement/Authorization for Publication and Conflict of Interest.
The article can only be submitted with these two documents.
To obtain the Authorship responsibility statement/Authorization for Publication file, click here.
To obtain the Conflict of Interest file (ICMJE template), click here
